By Josh Beckerman
Alnylam Pharmaceuticals' amyloidosis drug Amvuttra received Food and Drug Administration approval for an expanded indication.
The drug was approved for treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart-failure visits.
Cantor Fitzgerald wrote that "The most important thing is that it's approved with a broad label: by this, we mean mortality language is in fact included on the front page" and that the language about urgent heart failure visits is a differentiator compared with other products.
Amvuttra was previously approved for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 20, 2025 18:47 ET (22:47 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。